Jaguar Health Signs $18M Partnership to Expand Mytesi & Canalevia Access | NewsOut

Healthcare and biotech investors: Jaguar Health (NASDAQ: JAGX), through its subsidiary Napo Pharmaceuticals, has signed a new partnership with Specialty Pharma, part of Future Pak, to market and manufacture its lead products Mytesi and Canalevia in the U.S.

Reporting from News Out, Ana Berry explains that the agreement includes $18 million upfront with potential milestone payments, secures reliable manufacturing, and supports expanded patient access. The update follows CEO Lisa Conte’s presentation at the Life and Partners Healthcare Investor Summit and a $350,000 short-term financing to support ongoing operations.

#JaguarHealth
#JAGX
#NapoPharmaceuticals
#BiotechNews
#HealthcareInvesting
#PharmaPartnership
#DrugManufacturing
#Mytesi
#Canalevia
#NASDAQ
#AnaBerry
#NewsOut
#PharmaIndustry